JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Clearside Biomedical Inc

Închisă

0.41 2.5

Rezumat

Modificarea prețului

24h

Curent

Minim

0.4

Maxim

0.42

Indicatori cheie

By Trading Economics

Venit

-917K

-8.2M

Vânzări

2M

2.3M

Marjă de profit

-352.918

Angajați

32

EBITDA

-102K

-4.8M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+773.81% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-34M

35M

Deschiderea anterioară

-2.09

Închiderea anterioară

0.41

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Clearside Biomedical Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 aug. 2025, 23:11 UTC

Câștiguri

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 aug. 2025, 22:45 UTC

Câștiguri

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 aug. 2025, 22:39 UTC

Câștiguri

Great-West Lifeco Logs Lower 2Q Profit

5 aug. 2025, 21:32 UTC

Câștiguri

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 aug. 2025, 00:00 UTC

Achiziții, Fuziuni, Preluări

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 aug. 2025, 00:00 UTC

Achiziții, Fuziuni, Preluări

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 aug. 2025, 00:00 UTC

Achiziții, Fuziuni, Preluări

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 aug. 2025, 00:00 UTC

Achiziții, Fuziuni, Preluări

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 aug. 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 aug. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 aug. 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 aug. 2025, 23:03 UTC

Market Talk
Câștiguri

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 aug. 2025, 22:22 UTC

Câștiguri

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 aug. 2025, 22:21 UTC

Câștiguri

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 aug. 2025, 22:20 UTC

Câștiguri

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 aug. 2025, 22:18 UTC

Câștiguri

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 aug. 2025, 22:17 UTC

Câștiguri

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 aug. 2025, 22:17 UTC

Câștiguri

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 aug. 2025, 22:16 UTC

Câștiguri

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 aug. 2025, 22:16 UTC

Câștiguri

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 aug. 2025, 22:15 UTC

Câștiguri

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 aug. 2025, 22:13 UTC

Câștiguri

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 aug. 2025, 22:13 UTC

Câștiguri

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 aug. 2025, 22:12 UTC

Câștiguri

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 aug. 2025, 22:12 UTC

Câștiguri

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 aug. 2025, 21:58 UTC

Câștiguri

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 aug. 2025, 21:30 UTC

Câștiguri

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 aug. 2025, 21:26 UTC

Câștiguri

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 aug. 2025, 21:23 UTC

Câștiguri

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 aug. 2025, 21:17 UTC

Câștiguri

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparație

Modificare preț

Clearside Biomedical Inc Așteptări

Obiectiv de preț

By TipRanks

773.81% sus

Prognoză pe 12 luni

Medie 3.67 USD  773.81%

Maxim 6 USD

Minim 2 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruClearside Biomedical Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

6 ratings

0

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.8417 / 0.8939Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.